# Wuhan Biocause Pharmaceutical Development Co., Ltd. – FDA Inspection, Aug 24, 2018

Source: https://www.keypedia.com/records/fda_inspections/wuhan-biocause-pharmaceutical-development-co-ltd/58c8650e-e596-4fd1-a0ef-b54e39889c78
Source feed: FDA_Inspections

> FDA inspection 1069379 of Wuhan Biocause Pharmaceutical Development Co., Ltd., August 24, 2018. Classification: Voluntary Action Indicated (VAI). Form 483 issued. 4 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1069379
- Company Name: Wuhan Biocause Pharmaceutical Development Co., Ltd.
- Inspection Date: 2018-08-24
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- [FDA Inspection 1267912 - 2025-03-14](https://www.keypedia.com/records/fda_inspections/wuhan-biocause-pharmaceutical-development-co-ltd/cf0802f0-fbd5-4ef6-8a2f-51da576523d8)
- FDA Inspection 982641 - 2016-07-22
- FDA Inspection 873586 - 2014-02-28
- FDA Inspection 680329 - 2010-07-23

## Related Officers

- [Issuing Officer](https://www.keypedia.com/people/tiara-n-brown-crosen/8255649d-25a9-49fa-a28d-0cdda922c0c3)

Company: https://www.keypedia.com/companies/wuhan-biocause-pharmaceutical-development-co-ltd/79c352a3-22a2-471e-abbe-1802683656eb

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
